III. Contraindications
- See Tumor Necrosis Factor Inhibitor
- Not approved for use in children
IV. Dosing
- See Monoclonal Antibody for preparation for use
- Background
- Injection sites include thigh, Abdomen and outer upper arm (rotate injection sites)
- Available as a Preloaded syringe or autoinjector
- Refrigerate and protect from light
- Allow to warm to room Temperature for 15 to 30 minutes before injection (decreased pain)
-
Ulcerative Colitis
- Start: 200 mg SQ week 0
- Next: 100 mg SQ week 2
- Next: 100 mg SQ every 4 weeks
-
Rheumatoid Arthritis, Psoriatic Arthritis, Akylosing Spondylitis
- SQ
- Maintenance: 50 mg SQ every month
- IV
- Induction: Infuse 2 mg/kg IV over 30 minutes at week 0 and 4 weeks
- Maintenance: Infuse 2 mg/kg IV over 30 minutes every 8 weeks
- SQ
V. Mechanism
- See Tumor Necrosis Factor Inhibitor
- Monoclonal Antibody against human Tumor Necrosis Factor alpha
VI. Precautions
- See TNF Inhibitor
- TNF Inhibitors predispose to serious infections and malignancy
- Prepare for TNF Inhibitor use with infection screening (e.g. Tuberculosis) and Immunizations
VII. Adverse Effects
VIII. Safety
- Considered safe in Lactation
- Unknown safety in pregnancy (registry exists)
IX. Resources
- Golimumab Injection Solution (DailyMed)
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- (2023) Drugs for Inflammatory Bowel Disease, Med Lett Drug Ther 65: 105-12
Images: Related links to external sites (from Bing)
Related Studies
| simponi (on 1/19/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| SIMPONI 50 MG/0.5 ML PEN INJEC | $10,843.33 per ml | |